|Bid||186.88 x 100|
|Ask||186.91 x 200|
|Day's Range||186.08 - 188.55|
|52 Week Range||133.64 - 191.10|
|PE Ratio (TTM)||17.04|
|Dividend & Yield||4.60 (2.45%)|
|1y Target Est||N/A|
A "biosimilar" version of the cancer drug Avastin — Genentech Inc.'s best-selling oncology treatment — was approved Thursday by the Food and Drug Administration, potentially crimping the $6 billion franchise of the South San Francisco-based drug maker's Swiss parent. The drug, which Amgen Inc. (AMGN) and partner Allergan plc (AGN) will sell as Mvasi, also is known by the scientific name bevacizumab. The drug regulator's approval allows it to be used to treat metastatic colorectal cancer and types of lung, kidney, cervical and brain cancers.
Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.
Learn how this immigrant entrepreneur built a $5 billion company from scratch. This is her story.